BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 16689452)

  • 1. [The plasma cell myeloma--molecular pathogenesis and target therapies].
    Hess U
    Ther Umsch; 2006 Apr; 63(4):233-6. PubMed ID: 16689452
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapy strategies for multiple myeloma: current status.
    Gisslinger H; Kees M
    Wien Klin Wochenschr; 2003 Aug; 115(13-14):451-61. PubMed ID: 13677263
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Molecular targeting therapy for multiple myeloma].
    Takatoku M
    Nihon Rinsho; 2007 Dec; 65(12):2345-50. PubMed ID: 18069281
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A longitudinal computed tomography study of lenalidomide and bortezomib treatment for multiple myeloma: trabecular microarchitecture and biomechanics assessed using multidetector computed tomography.
    Takasu M; Tani C; Kaichi Y; Sakoda Y; Kiguchi M; Date S; Kuroda Y; Sakai A; Awai K
    Clin Lymphoma Myeloma Leuk; 2014 Dec; 14(6):485-92. PubMed ID: 25190250
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted therapy in multiple myeloma.
    Chng WJ; Lau LG; Yusof N; Mow BM
    Cancer Control; 2005 Apr; 12(2):91-104. PubMed ID: 15855892
    [TBL] [Abstract][Full Text] [Related]  

  • 6. (Bortezomib plus lenalidomide/thalidomide)- vs. (bortezomib or lenalidomide/thalidomide)-containing regimens as induction therapy in newly diagnosed multiple myeloma: a meta-analysis of randomized controlled trials.
    Wang A; Duan Q; Liu X; Ding K; Han Y; Zhu W; Cai X; Wu J; Sun Z
    Ann Hematol; 2012 Nov; 91(11):1779-84. PubMed ID: 22773209
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nontraditional cytotoxic therapies for relapsed/refractory multiple myeloma.
    Hussein MA
    Oncologist; 2002; 7 Suppl 1():20-9. PubMed ID: 11961206
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple myeloma.
    Raab MS; Podar K; Breitkreutz I; Richardson PG; Anderson KC
    Lancet; 2009 Jul; 374(9686):324-39. PubMed ID: 19541364
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel agents in the frontline management of multiple myeloma.
    Loong HH
    Hematol Oncol Stem Cell Ther; 2008; 1(4):201-9. PubMed ID: 20058474
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pomalidomide for multiple myeloma.
    Fouquet G; Bories C; Guidez S; Renaud L; Herbaux C; Javed S; Facon T; Leleu X
    Expert Rev Hematol; 2014 Dec; 7(6):719-31. PubMed ID: 25265911
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of double-refractory multiple myeloma.
    Meadows JP; Mark TM
    Curr Hematol Malig Rep; 2013 Dec; 8(4):253-60. PubMed ID: 23975677
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel therapies in myeloma.
    Hayden PJ; Mitsiades CS; Anderson KC; Richardson PG
    Curr Opin Hematol; 2007 Nov; 14(6):609-15. PubMed ID: 17898564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel agents for relapsed and/or refractory multiple myeloma.
    Thomas SK; Richards TA; Weber DM
    Cancer J; 2009; 15(6):485-93. PubMed ID: 20010168
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [New treatment of multiple myeloma].
    Hulin C
    Rev Med Interne; 2007 Oct; 28(10):682-8. PubMed ID: 17559982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The emerging role of arsenic trioxide as an immunomodulatory agent in the management of multiple myeloma.
    Kalmadi SR; Hussein MA
    Acta Haematol; 2006; 116(1):1-7. PubMed ID: 16809883
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Understanding novel therapeutic agents for multiple myeloma.
    Tariman JD
    Clin J Oncol Nurs; 2003; 7(5):521-8. PubMed ID: 14603548
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New drugs for myeloma.
    Richardson PG; Mitsiades C; Schlossman R; Munshi N; Anderson K
    Oncologist; 2007 Jun; 12(6):664-89. PubMed ID: 17602058
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of the bone marrow microenvironment in multiple myeloma.
    Roodman GD
    J Bone Miner Res; 2002 Nov; 17(11):1921-5. PubMed ID: 12412796
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical update: novel targets in multiple myeloma.
    Anderson KC
    Semin Oncol; 2004 Dec; 31(6 Suppl 16):27-32; discussion 33. PubMed ID: 15799242
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnosis and the current trends in multiple myeloma therapy.
    DmoszyƄska A
    Pol Arch Med Wewn; 2008 Oct; 118(10):563-6. PubMed ID: 19112817
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.